According to TipRanks.com, Deakin-Bell is a 2-star analyst with an average return of 2.7% and a 66.7% success rate. Deakin-Bell covers the Healthcare sector, focusing on stocks such as Pro Medicus Limited, Nanosonics Limited, and Ramsay Health Care.
Mayne Pharma Group Limited has an analyst consensus of Hold, with a price target consensus of $0.19.
The company has a one-year high of $0.42 and a one-year low of $0.15. Currently, Mayne Pharma Group Limited has an average volume of 16.52K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment involves in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty brands segments includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment offers manufacturing and selling of branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.
Read More on MAYNF: